Published on February 13, 2018
Sattva S. Neelapu, MD, discusses the safety and practical implications for axi-cel (KTE-C19) as part of the ZUMA-1 trial, as well as the future for CAR T-cellular therapy in lymphoma.
Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma
